Omeros Corporation today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement.
[More]
Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.
[More]
Sydney researchers have discovered a new type of immune cell in skin that plays a role in fighting off parasitic invaders such as ticks, mites, and worms, and could be linked to eczema and allergic skin diseases.
[More]
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A., today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.
[More]
In a serendipitous discovery, scientists at The Scripps Research Institute have found a way to turn bone marrow stem cells directly into brain cells.
[More]
Snot. It's not something most of us spend a lot of time thinking about, but, for a team of researchers in Washington, D.C., it's front and center.
[More]
According to a study published in the Journals of Gerontology Series A: Biological Sciences and Medical Sciences, a baseline adherence to a Mediterranean diet (MeDiet) is associated with a lower risk of hyperuricemia, defined as a serum uric acid (SUA) concentration higher than 7mg/dl in men and higher than 6mg/dl in women.
[More]
Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life.
[More]
A parasitic worm may hold the answer to keeping skin grafts firmly in place over wounds, according to a new study by researchers at Brigham and Women's Hospital (BWH).
[More]
Mast Therapeutics, Inc. today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.
[More]
Atherosclerosis - sometimes called "hardening of the arteries" - is a leading cause of death and morbidity in Western countries. A cell-permeable peptide containing the NF-ĸB nuclear localization sequence (NLS) shows promise as a potential agent in controlling the development of atherosclerotic disease.
[More]
Researchers may have found a way to block kidney-destroying inflammation and help damaged kidney cells recover.
[More]
Migraine affects an estimated 30 million people in the U.S, with the one year prevalence of migraine estimated at 12% of the general population, including 18% of all women and 6% of all men.
[More]
A potential new strategy to developing new drugs to control inflammation without serious side effects has been found by Georgia State University researchers and international colleagues.
[More]
Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
[More]
Anacor Pharmaceuticals today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis.
[More]
Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.
[More]
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.
[More]
Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver. Now researchers have found that male smokers with low levels of the yellow-tinged chemical are at higher risk for lung cancer and dying from the disease.
[More]
On April 8 at 11 a.m., thousands of people will gather on the Carnegie Library grounds to participate in the Rally for Medical Research to raise awareness of the critical need to make funding for the National Institutes of Health a priority.
[More]